Tempus AI (NASDAQ:TEM) CFO James William Rogers Sells 7,079 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) CFO James Rogers sold 7,079 shares of the company’s stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $63.02, for a total transaction of $446,118.58. Following the completion of the transaction, the chief financial officer owned 98,945 shares of the company’s stock, valued at approximately $6,235,513.90. The trade was a 6.68% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Stock Down 6.3%

Shares of NASDAQ TEM traded down $4.01 during mid-day trading on Thursday, reaching $59.61. The company had a trading volume of 5,290,938 shares, compared to its average volume of 6,229,094. The firm has a 50 day simple moving average of $72.87 and a two-hundred day simple moving average of $57.56. Tempus AI, Inc. has a 52-week low of $40.77 and a 52-week high of $89.09. The company has a current ratio of 2.61, a quick ratio of 2.48 and a debt-to-equity ratio of 2.70. The stock has a market cap of $10.87 billion, a P/E ratio of -56.24 and a beta of 3.61.

Tempus AI (NASDAQ:TEM – Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.16. Tempus AI had a negative net margin of 12.54% and a negative return on equity of 47.00%. The firm had revenue of $411.54 million during the quarter, compared to analysts’ expectations of $409.39 million. During the same period in the previous year, the company earned ($0.46) earnings per share. Tempus AI’s quarterly revenue was up 23.1% compared to the same quarter last year. Sell-side analysts predict that Tempus AI, Inc. will post -1.20 earnings per share for the current year.

Key Tempus AI News

Investors following TEM have been watching these news items:

  • Positive Sentiment: Tempus will present 16 abstracts at the 2026 San Antonio Breast Cancer Symposium. The research exposure could showcase its oncology data and precision-medicine capabilities, though the headline does not disclose results or commercial impact. Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium
  • Positive Sentiment: A recent investor-focused article cites data agreements expected to generate $193 million over five years and oncology pricing changes expected to add $80 million in average selling price during 2027. These figures offer potential revenue support, although they depend on execution and timing. Tempus AI: 3 Key Takeaways for Long-Term Investors
  • Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $85 price target, indicating substantial potential upside from the cited $59.61 reference price. This is analyst opinion, not a guarantee of performance. HC Wainwright rating information

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on TEM shares. Rothschild & Co Redburn started coverage on Tempus AI in a report on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 target price for the company. Canaccord Genuity Group raised their price target on Tempus AI from $80.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, October 12th. Piper Sandler raised Tempus AI from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $56.00 to $76.00 in a research report on Tuesday, September 1st. Needham & Company LLC boosted their price objective on Tempus AI from $75.00 to $89.00 and gave the company a “buy” rating in a research note on Monday, November 2nd. Finally, Roth Capital started coverage on Tempus AI in a report on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 price objective for the company. Eleven research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $79.37.

Read Our Latest Stock Analysis on TEM

Institutional Trading of Tempus AI

Several hedge funds have recently made changes to their positions in TEM. V Square Quantitative Management LLC purchased a new stake in shares of Tempus AI in the third quarter valued at about $27,000. EMC Capital Management purchased a new position in Tempus AI during the second quarter worth about $29,000. Edmond DE Rothschild Holding S.A. purchased a new position in Tempus AI during the third quarter worth about $33,000. Ulland Investment Advisors LLC purchased a new position in Tempus AI during the third quarter worth about $41,000. Finally, Heritage Family Offices LLP acquired a new stake in Tempus AI in the third quarter valued at about $45,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

About Tempus AI

(Get Free Report)

Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.

See Also

Insider Buying and Selling by Quarter for Tempus AI (NASDAQ:TEM)

Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.